Novo Nordisk er ikke immun over for Donald Trumps told, men selskabet har investeret massivt i at kunne producere mere i USA ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Mens et af Europas mest værdifulde selskaber rutsjer rundt på børsen, shopper profitjægere løs Selvom nedgangen har været ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk .

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, ...

Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...

Novo Nordisk stock reported strong sales growth but lowered sales forecasts this morning. The good news: 2025 earnings will grow faster than sales. Novo Nordisk reports its results in Danish ...